Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Hypertension

Free Subscription 10.11.2025 2 Eur Heart J 1 Eur J Pharmacol 4 Hypertension 1 J Cardiovasc Pharmacol 3 J Hum Hypertens 17 J Hypertens 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Eur Heart J

1. FATIMA M, Sheikh S, Ammer Z
   Bridging The Gaps In EMPEROR-Preserved: Toward safer and smarter use of Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction.
   Eur Heart J. 2025 Nov 4:ehaf799. doi: 10.1093.
   PubMed        
   
   
2. TOKCAN M, Markwirth P, Bohm M
   Uniform benefits of empagliflozin across hypertension categories: a response.
   Eur Heart J. 2025 Nov 4:ehaf798. doi: 10.1093.
   PubMed        
   
   

   
   Eur J Pharmacol

3. BAI Y, Jiang Y, Zhou Y, Xia Y, et al
   The Role of Ferroptosis in the Pathogenesis of Pulmonary Hypertension and Its Therapeutic Potential.
   Eur J Pharmacol. 2025 Nov 1:178316. doi: 10.1016/j.ejphar.2025.178316.
   PubMed         Abstract available
   
   

   
   Hypertension

4. MAISONS V, Demir F, Fillon A, Delalande P, et al
   Renal Histology Findings in Malignant Hypertension, a Systematic Review.
   Hypertension. 2025 Nov 4. doi: 10.1161/HYPERTENSIONAHA.125.25069.
   PubMed         Abstract available
   
   
5. CHOI H, Panja S, Nguyen HN, Stark RJ, et al
   Smooth Muscle LRRC8A Knockout Preserves Vascular Function in Ang II Hypertension.
   Hypertension. 2025 Nov 4. doi: 10.1161/HYPERTENSIONAHA.125.25222.
   PubMed         Abstract available
   
   
6. KARIO K, Tomitani N, Harada N, Morimoto T, et al
   Efficacy Determinants of Hypertension Digital Therapeutics: The B-INDEX Study.
   Hypertension. 2025 Nov 3. doi: 10.1161/HYPERTENSIONAHA.125.25028.
   PubMed         Abstract available
   
   
7. ZAND J, Miao J, Hommos MS, Schwartz GL, et al
   Performance of Large Language Models in Analyzing Common Hypertension Scenarios.
   Hypertension. 2025 Nov 3. doi: 10.1161/HYPERTENSIONAHA.125.25492.
   PubMed         Abstract available
   
   

   
   J Cardiovasc Pharmacol

8. BIONDI-ZOCCAI G, Abbate A, Booz GW
   Baxdrostat: the new kid on the block for the treatment of resistant hypertension.
   J Cardiovasc Pharmacol. 2025 Nov 5. doi: 10.1097/FJC.0000000000001771.
   PubMed        
   
   

   
   J Hum Hypertens

9. ANGEL-KORMAN A, Mayer O, Brosh-Nissimov T, Leiba A, et al
   Infection with COVID-19 does not increase blood pressure in patients with chronic kidney disease.
   J Hum Hypertens. 2025;39:777-783.
   PubMed         Abstract available
   
   
10. ARGYRIS AA, Baker D, Charnley P, Howe L, et al
    Effect of digital messaging on blood pressure control in general practice: observations from the BP@Home programme in wirral area.
    J Hum Hypertens. 2025;39:770-776.
    PubMed         Abstract available
    
    
11. PARIS NS, Okawa RTP, Lopes WA
    The need to distinguish office and ambulatory blood pressure in evaluating Pilates efficacy in hypertension.
    J Hum Hypertens. 2025 Nov 1. doi: 10.1038/s41371-025-01091.
    PubMed        
    
    

    
    J Hypertens

12. MANDAL AK, Rana T, Shrestha S, Mat Hassan MK, et al
    Effectiveness of aerobic exercise in reducing blood pressure among obese adults: systematic review and meta-analysis.
    J Hypertens. 2025;43:1923-1936.
    PubMed         Abstract available
    
    
13. BEZERRA R, Feitosa ADM, Guimaraes-Neto VS, Barbosa R, et al
    Achieving blood pressure control with monotherapy: real-world evidence from office and home blood pressure measurements.
    J Hypertens. 2025;43:2075-2078.
    PubMed         Abstract available
    
    
14. ROCHE-GOMEZ A, Blazquez Gomez CJ, Licero Villanueva A, Espino Hernandez M, et al
    Novel homozygous pathogenic variant in HSD11B2 as a cause of apparent mineralocorticoid excess.
    J Hypertens. 2025;43:2072-2074.
    PubMed         Abstract available
    
    
15. ZHANG Y, Tian P, Zeng F, Huang B, et al
    Computed tomography-guided ozone neurolysis lowers blood pressure.
    J Hypertens. 2025;43:2079-2085.
    PubMed         Abstract available
    
    
16. PASDAR Z, Chandanani M, Dhillon N, Carter B, et al
    Hypertensive disorders of pregnancy increase the risk of future ophthalmic disorders: a systematic review and meta-analysis.
    J Hypertens. 2025;43:1903-1911.
    PubMed         Abstract available
    
    
17. JIANG Q, Ji G, Huang P, Huang X, et al
    Trend in hypertension prevalence, awareness, treatment, and control rates among adult residents in Guangdong province, southern China, 2002~2022.
    J Hypertens. 2025;43:1953-1962.
    PubMed         Abstract available
    
    
18. LIU C, Wang J, Chi J, Dong Y, et al
    Inhibition of calcium-sensitive receptors ameliorates myocardial fibrosis, in Dahl salt-sensitive rats.
    J Hypertens. 2025;43:1972-1983.
    PubMed         Abstract available
    
    
19. ANTZA C, Anyfanti P, Kotoulas SC, Kotsis V, et al
    Diagnostic accuracy of blood pressure measurement methods for hypertension screening in obesity: does one fit all?
    J Hypertens. 2025;43:1991-1998.
    PubMed         Abstract available
    
    
20. CAI A, Cheng Q, Zhou D, Feng X, et al
    Risk reclassification and cost-effectiveness of echocardiography for cardiovascular primary prevention in hypertension in China.
    J Hypertens. 2025;43:1999-2007.
    PubMed         Abstract available
    
    
21. ROSTAMIAN S, Kaura A, Ariti C, Gupta A, et al
    The impact of blood pressure variability on cardiovascular and renal outcomes in patients with and without diabetes: insights from the Anglo-Scandinavian Cardiac Outcomes Trial.
    J Hypertens. 2025;43:2033-2041.
    PubMed         Abstract available
    
    
22. DENG B, Liu W
    Advancing understanding of racial disparities in hypertension: does Factor IX illuminate or confound?
    J Hypertens. 2025;43:2086-2087.
    PubMed        
    
    
23. PANG G, Wang L
    From cost savings to clinical benefits: thoughts on economic evaluation of single pill combinations in hypertension.
    J Hypertens. 2025;43:2088-2089.
    PubMed        
    
    
24. STOUTENBURG EG, Long DL, Plante TB
    Considerations on conducting observational research of thromboinflammation and incident hypertension.
    J Hypertens. 2025;43:2090.
    PubMed        
    
    
25. ATKINS ER, Pikkemaat M, Rodgers A, Schutte AE, et al
    Reply to comment: Treating hypertension with single pill combinations: a simple strategy to save costs for the patients and payers.
    J Hypertens. 2025;43:2091.
    PubMed        
    
    
26. MEMON ME, Aun SM
    Letter to the editor: limitations in assessing long term risks after hypertensive emergencies.
    J Hypertens. 2025;43:2092.
    PubMed        
    
    
27. BUCCI T, Lip GYH
    Reply: risk estimation following hypertensive crises.
    J Hypertens. 2025;43:2094.
    PubMed        
    
    
28. SCHLAICH MP, Weber MA, Flack JM, Danaietash P, et al
    Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension.
    J Hypertens. 2025 Oct 2. doi: 10.1097/HJH.0000000000004174.
    PubMed         Abstract available
    
    

    
    PLoS One

29. MEDDAR JM, Mann D, Schwartz M, Park HG, et al
    Associations between remote patient monitoring and uncontrolled blood pressure among patients diagnosed with hypertension: Exploring variations by race/ethnicity.
    PLoS One. 2025;20:e0334887.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge.